Categories
Archives
- 2026
- 2025
- 2024
- 2023
Nov
26
UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting
Nov
20
Closing gaps in HS care through community engagement and scientific innovation
Nov
14
New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis
Oct
15
Powering the dreams of people impacted by myasthenia gravis (MG)
Oct
15
UCB announces U.S. launch of UCB Myasthenia Gravis Scholarship™ for people impacted by myasthenia gravis in the U.S.
Oct
14
UCB Receives U.S. FDA Approval for 320 mg Single-Injection Device Presentations of BIMZELX® (bimekizumab-bkzx)
Oct
11
UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session
Sep
23
UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
Sep
23
Redefining Immunology Care: Our Pledge to Patients and the Healthcare Community
